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Abstract MicroRNAs (miRs) are short endogenous non-
coding RNAs that act as posttranscriptional regulatory factors
of gene expression. Downregulation of miR-1 has been re-
ported in gastric cancer; however, the mechanisms underlying
its functions via target genes in gastric cancer remain largely
unknown. The purpose of this study was to investigate the
mechanism by which miR-1 inhibits gastric cancer cell prolif-
eration and migration. The effects of miR-1 on gastric cancer
cell proliferation and migration were determined by MTT and
wound-healing assays. Cell protein expression of the miR-1
target gene MET was analyzed by Western blotting. Finally,
METexpression was evaluated by immunohistochemistry in a
stomach tumor tissue microarray (TMA). Ectopic expression
of miR-1 inhibited proliferation and migration in both AGS
and SGC-7901 gastric cancer cell lines. miR-1 directly targets
the MET gene and downregulates its expression. METsiRNA
also inhibited proliferation and migration in both cell lines.
Immunohistochemistry revealed significantly higher METex-
pression levels in gastric cancer tissues compared with
matched adjacent non-cancer tissues. These findings indicate
that the miR-1/MET pathway is a potential therapeutic target
due to its crucial role in gastric cancer cell proliferation and
migration.
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Gastric cancer is the fourth most common malignancy world-
wide. It is more common in men and in developing countries,
including East Asian and Eastern European nations. There
were approximately 700,000 gastric cancer deaths in 2012,
making this malignancy the third leading cause of cancer
death after lung and liver cancers [1, 2]. Treatment of stomach
cancer may include surgery, adjuvant chemotherapy, and/or
radiation therapy. Despite the demonstrated benefits of these
treatments, gastric cancer remains virtually incurable with the
metastatic disease. Therefore, it is urgent to improve the over-
all survival rate of patients with gastric cancer by identifying
novel therapeutic strategies.
MicroRNAs (miRs) are endogenous small non-coding
RNA molecules that bind to complementary sequences in
specific regions of multiple target mRNAs to act as posttran-
scriptional gene expression regulators [3, 4]. MiRs impair
gene expression by repressing translation or promoting
mRNA degradation. Dysregulation of miRs therefore
* Quancheng Kan
quanchengkan@yeah.net
1 Department of Clinical Pharmacology, The First Affiliated Hospital
of Zhengzhou University, Zhengzhou 450052, People’s Republic of
China
2 Department of Infectious Diseases, The First Affiliated Hospital of
Zhengzhou University, Zhengzhou, People’s Republic of China
3 Department of Endocrinology and Metabolism, The First Affiliated
Hospital of Zhengzhou University, Zhengzhou, People’s Republic of
China
4 Sarcoma Biology Laboratory, Center for Sarcoma and Connective
Tissue Oncology, Massachusetts General Hospital, Boston, MA,
USA
Tumor Biol. (2015) 36:6715–6723
DOI 10.1007/s13277-015-3358-6
interferes with many biological processes such as cell prolif-
eration, metabolism, differentiation, apoptosis, immunity, and
development [5–9]. Moreover, multiple studies have shown
that miRs play an important role in human cancers; they could
be used as diagnostic and prognostic cancer biomarkers and
even be applied to therapy [10, 11]. MicroRNA-1 (miR-1) is a
known tumor suppressor that is downregulated in several
types of malignancies such as lung cancer, colorectal cancer,
prostate cancer, bladder cancer, rhabdomyosarcoma, and
chordoma [12–17]. It has also been shown that miR-1 is
underexpressed in gastric cancer compared to normal stomach
epithelium, in line with its potential tumor suppressor role
[18]. However, other studies have demonstrated that miR-1
levels are increased in gastric cancer samples compared with
the control samples [19]. These inconsistencies indicate that
miR-1 and its function need further characterization.
The MET gene is a direct target of miR-1 [4, 10]. MET is a
known oncogene that encodes a cell surface receptor tyrosine
kinase, which is upregulated in a variety of human cancers
[20–22]. The activation of MET is due to binding of hepato-
cyte growth factor (HGF), followed byMET dimerization and
auto-phosphorylation. These events contribute to tumor
growth, metastasis, migration, and drug resistance [23, 24].
Furthermore,MET has been used as a target to improve cancer
therapy and ameliorate the sensitivity of chemotherapy in dif-
ferent cancers [25, 26]. MET has been predicted and con-
firmed to be a target gene for multiple miRs, including miR-1.
In this study, we investigated the functions of miR-1 in
gastric cancer cell proliferation and migration. Specifically,
we focused on the miR-1 target gene MET to determine its
expression in gastric tumor tissues.
Materials and methods
Cell culture
Human gastric cancer cell lines AGS and SGC-7901 were
purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Both cell lines were grown in
RPMI-1640 medium containing 10 % fetal bovine serum
(FBS), 100 units/ml of penicillin, and 100 μg/ml streptomy-
cin. Cells were cultured in a humidified atmosphere contain-
ing 5 % CO2 at 37 °C.
MicroRNA mimics transfection and siRNA treatment
The following RNA products were used in this research: hsa-
miR-1mimics, negative control miRmimics, small interfering
RNA (siRNA), and negative control siRNA mimics; these
RNA products were chemically synthesized by Shanghai
GenePharma Co. Ltd. A total of 2×105 cells in 2 ml of culture
medium were seeded per well of a six-well plate 1 day before
transfection. For transfection, miR or siRNA sample was
mixed with LipofectamineTM RNAiMax (Invitrogen, CA,
USA), then Opti-MEM (Invitrogen, CA, USA) was added
dropwise into the well after incubation for 10 min.
RNA extraction and real-time PCR for quantification
of miR-1
For detecting the expression of miR, total RNA from cells
were harvested by TRIzol (Invitrogen, CA, USA) reagent.
SYBR Green real-time PCR (RT-PCR) was performed to val-
idate expressed miR-1 after transfection of miR-1 mimics. For
mature miR-1 detection, cDNA reverse transcription was per-
formed from total RNA samples using specific miR-1 primers
from the SYBR Green MicroRNA Assays and reagents from
the miR Reverse Transcription Kit (Novland Biopharma,
Shanghai, China).
Cell proliferation and motility assays
Cells were transfected with various amounts of miR-1 mimics
and siRNA by reverse transfection according to the manufac-
turer’s instructions and plated at a density of 4×103 cells per
well in 96-well plates. After 72 h, cell proliferation was de-
tected by MTT (Sigma-Aldrich, Saint Louis, MO, USA) as-
say. For each treatment group, triplicate wells were analyzed
for cell viability.
To evaluate cell motility, a wound-healing assay was car-
ried out. AGS cells were plated in six-well plates at 2×105
cells per well, and wounds were generated using a micropi-
pette tip. Then, cells were rinsed three times with phosphate-
buffered saline and fresh culture medium was added. The
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after 48 and 72 h of wound establishment. The wound-healing
assays were repeated three times. The data were then analyzed
using Prism 5.0 software and expressed as mean±SEM.
Western blot analysis
AGS and SGC-7901 cells were seeded in six-well plates (2×
105 cells/well) and cultured in RPMI-1640 containing 10 %
FBS for 24 h. After transfection for 72 h, the cells were
washed with cold phosphate-buffered saline and subjected to
lysis with RIPA lysis buffer (50 mMTris-HCl, 150 mMNaCl,
1 % Triton X-100, 1 % sodium deoxycholate, 0.1 % SDS, and
other protease inhibitors) on ice. Afterward, equal amounts of
protein lysate (30 μg) and Precision Plus Protein™ Dual Col-
or Standards (Cat#: 161-0374, Bio-Rad, Hercules, CA, USA)
were separated by NuPAGE on 4–12 % bis-tris gel
(Invitrogen, CA, USA), transferred onto nitrocellulose mem-
branes and blocked in 5 % non-fat milk for 1 h. Immunoblot-
ting was carried out overnight with diluted polyclonal anti-
bodies against MET (1:500; Santa Cruz Biotechnology,
USA), survivin (1:1000), and beta-actin (1:3000). Afterward,
the membranes were washed three times with TBS-T and in-
cubated with IRDye 680LT Goat anti-rabbit (H+L) (1: 5000)
or IRDye 800CW goat anti-mouse (H+L) (1:15,000; Li-COR
Biosciences, Lincoln, NE, USA) for 2 h at room temperature.
The bound complexes were detected by using the Odyssey
Infrared Imaging System (Li-COR, Lincoln, NE, USA), and
images were analyzed with the Odyssey Application
Software.
Tissue microarray assay
To assess MET expression in human gastric cancers, a set of
gastric cancer tissue microarray (TMA) was purchased from
Shanghai Outdo Biotech (OD-CT-DgStm01-014, Shanghai,
China). The TMA contained 75 gastric cancer tissues with
matched adjacent non-gastric cancer tissues (Table 1).
Rabbit-derived anti-human MET antibody (1:200 dilution,
Santa Cruz Biotechnology, USA) was used for immunohisto-
chemical (IHC) detection of the MET protein in TMA sam-
ples. Endogenous peroxidase was inhibited by incubation
with freshly prepared 3 % hydrogen peroxide containing
0.1 % sodium azide. TMA was successively incubated with
goat anti-rabbit antibodies and ExtrAvidin-conjugated horse-
radish peroxidase. Staining was developed with the diamino-
benzidine (DAB) substrate, and sections were counterstained
with hematoxylin. The proportion of positively stained tumor
cells was staged as follows: 0 (no positive membrane staining
ofMET tumor cells), 1+ (<25% positive tumor cells), 2+ (25–
50% positive tumor cells), 3+ (50–75% positive tumor cells),
and 4+ (>75 % positive tumor cells).
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
5.0 software. For comparison between MET expression and
clinical/pathologic variables, a two-sided Student t test was
used. Statistical significance is described in the figures and
respective legends. For comparison between MET expression
Fig. 1 Transfection with miR-1 inhibits gastric cancer AGS and SGC-
7901 cell growth. a, b To verify the expression levels of miR-1 in these
two gastric cancer cell lines after transfecting miR-1 mimics for 48 h. c, d
AGS and SGC-7901 cells were transfected with miR-1 mimics and non-
specific miR mimics at 5–80 nM, respectively, and incubated for up to
72 h in a medium containing 10 % FBS. Cell growth was measured by
MTT-based cell proliferation assay. The experiment was performed in
triplicate
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and immune infiltrates, a one-wayANOVA analysis was used.
P<0.05 was considered statistically significant.
Results
Ectopic expression of miR-1 inhibits gastric cancer cell
proliferation and motility in vitro
To understand the potential function of miR-1 in gastric can-
cer, MTT assay was carried out to assess the proliferation of
gastric cancer cells after transfection with miR-1 mimics. As
shown in Fig. 1a, b, the expression levels of miR-1 were
upregulated in these two gastric cancer cell lines as confirmed
by SYBRGreen real-time RT-PCR. Then we performedMTT
to determine the function of miR-1. The results showed that
the two gastric cancer cell lines were significantly inhibited in
miR-1 transfectants in comparison with cells transfected with
the non-specific miR negative control (Fig. 1c, d). These
results indicated that overexpression of miR-1 inhibited pro-
liferation of gastric cancer cells in a dose-dependent manner
in vitro (Fig. 1). Furthermore, wound-healing assay data
showed significantly different widths for the residual gaps
obtained in the miR-1 transfection and non-specific miR con-
trol groups, especially at 72 h (Fig. 2, P<0.001). This exper-
iment was repeated for three times.
MET is a direct target for miR-1 in gastric cancer
To assess the mechanism by which miR-1 inhibits gastric
cancer cell growth, miR-1 mimics (40 nmol/L) were intro-
duced into proliferating AGS and SGC-7901 cells. As shown
in Fig. 3, MET protein expression was significantly downreg-
ulated in miR-1 transfectants in comparison with the control
cells. These results indicated that MET is a common target
gene for miR-1. In AGS and SGC-7901, the expression levels
of METwere downregulated to 32 and 35.4 %, respectively.
Fig. 2 Ectopic expression of miR-1 reduces cell motility in the wound
scratch assay. a AGS cells were seeded in six-well plates at 2×105 cells
per well. Wounds were generated using a micropipette tip upon cell
adherence. Then, cells were transfected with miR-1 and non-specific
miR mimics. The extent of wound healing was monitored by phase
contrast microscopy, and photomicrographs were acquired at 48 and
72 h. b, c Quantification of cell migration using the monolayer wound-
healing assay. The data were then analyzed using Prism 5.0 software and
expressed as mean±SEM
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MET silencing inhibits gastric cancer cell growth
MET is known to be associated with carcinoma in various
cancer types. The expression level of the MET protein was
significantly decreased in both gastric cancer cell lines (AGS
and SGC-7901) after transfection with miR-1 mimics (Fig. 3).
In addition, the expression levels of survivin were also
inhibited in both two cell lines (Fig. 3c, f). Conversely, MET
expression was markedly reduced in MET siRNA (si-MET)
transfectants. Specifically, inhibition of MET expression in
AGS cells was more robust compared with that obtained for
the SGC-7901 cell line (Fig. 4). AS expected, there are no
significant changes on the expression levels of survivin in
MET siRNA transfected cells. Loss-of-function assays using
siRNA analysis were performed to examine the effect of MET
on gastric cancer cell growth. The MTTassay revealed signif-
icant cell growth inhibition in si-MET-1/2/3 transfected cells
after a 72-h transfection (Fig. 5).
Fig. 3 MET protein expression inmiR-1 transfectants. aMiR-1 and non-
specific miR mimics were transfected into AGS cells, respectively. MET
and survivin protein expression levels were determined after 72 h. b, c
Quantification of protein expression using the Odyssey Infrared Imaging
System and the application software. The data indicate that MET and
survivin protein expression levels were suppressed by 68 and 71.9 %,
respectively. d, e, f MET and survivin protein expression in SGC-7901
cells. Both proteins were downregulated by 64.6 and 41.6 %, respectively
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Fig. 4 The MET protein was downregulated by siRNA in AGS and SGC-
7901 cells. a si-MET-1/2/3 mimics and non-specific siRNA mimics were
transfected into AGS cells. METand survivin protein expression levels were
determined after 72 h. b The data showed that MET protein expression
levels were suppressed by 96.74, 95.86, and 94.95 %, respectively, for si-
MET-1, 2, and 3. c Relative expression of survivin protein in AGS cells. d
MET protein expression in SGC-7901 cells. e The protein expression was
inhibited by 46.9, 61.2, and 54.8 %, respectively, after transfection with si-
MET-1, 2, and 3. f Relative of survivin protein in SGC-7901 cells. The
densities of the bands of MET and survivin expression were then quantified
by Odyssey software 3.0 (LI-COR Biosciences). The data were then ana-
lyzed using Prism 5.0 software and expressed as mean±SEM
Fig. 5 MET siRNA inhibits AGS and SGC-7901 cell growth. a, c AGS
cells were transfected with si-MET-1/2/3 mimics and non-specific siRNA
mimics at 5–80 nM, respectively, and incubated for up to 72 h in a
medium containing 10 % FBS. b SGC-7901 cells were transfected with
si-MET-1/2/3 mimics and non-specific miR mimics at 5–80 nM and
incubated for 72 h. Cell growth was measured as described above
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MET expression level is higher in gastric cancer tissues
than matched specimens
We further investigated the underlying molecular mechanism
of growth inhibition in gastric cancer cells bymiR-1. MET is a
well-known direct target gene for miR-1. We measured MET
protein expression in the gastric cancer cell lines AGS and
SGC-7901 by Western blot. We found that MET was signifi-
cantly downregulated in miR-1 transfected cell lines (Fig. 3).
We further determined MET expression in the tissue microar-
ray (TMA) which consisted of 75 gastric cancer tissues with
75 matched adjacent non-gastric cancer tissues. The degree of
immunostaining of TMA samples was evaluated separately by
two independent investigators, who were blinded to patient
details and sample’s histopathological features (Fig. 5). By
comparing MET expression between gastric cancer tissues
and adjacent non-gastric cancer specimens, we found that
the average expression level of MET was higher in gastric
cancer tissues (Fig. 6f, g).
Discussion
Recent studies have demonstrated that different miRs contrib-
ute to many fundamental biological processes, including the
carcinogenesis of gastric cancer [10, 18, 19]. In the present
study, we found that miR-1 inhibits gastric cell proliferation
and migration by targeting MET, in agreement with several
recent studies suggesting that MET is a direct miR-1 target
gene [16, 27].
Recent studies have shown the low expression level of
miR-1 in other types of cancers compared with matched
Fig. 6 Expression of MET in gastric cancer tissues and adjacent
specimens as analyzed by IHC. Representative results of MET staining
micrographs of gastric tissues (×20). A1–E1Hematoxylin and eosin (HE)
staining of gastric cancer tissues. A2–E2According to their staining, cells
were divided into negative, 1+ (<25% positive tumor cells), 2+ (25–50%
positive tumor cells), 3+ (50–75 % positive tumor cells), and 4+ (>75 %
positive tumor cells). F andG represent gastric cancer tissue and matched
adjacent samples. h It shows that average expression of MET in gastric
cancer tissues were higher than the matched tissues (P<0.0001)
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normal tissues [16, 28–30].We also demonstrated that MET is
highly expressed in gastric tumor tissues compared with
matched normal tissues. Ectopic re-expression of miR-1 has
been found to inhibit various types of cancers [31, 32]. Fur-
thermore, multiple studies have shown that overexpression of
miR-1 in non-miR-1-expressing lung cancer cells reverses
their tumorigenic properties of growth, replication potential,
motility/migration, clonogenic survival, and tumor formation
in nude mice [30]. In hepatocellular carcinoma cells, miR-1
inhibits cell growth and reduces the replication potential and
clonogenic survival [9, 29, 33]. Similarly, overexpression of
miR-1 was shown to inhibit prostate cancer cell proliferation,
migration, wound healing, and invasion activity [34]. Besides,
ectopic expression of miR-1 has equal features of can-
didate tumor suppressor in other human cancers [32, 35]. Our
current collectively showed that ectopic expression of miR-1
inhibited proliferation and migration in gastric cancer cells.
miR-1 directly targets the MET gene and downregulates its
expression.
MiRs cannot directly play their biological roles: they bind
to the 3′-untranslated regions (UTRs) of target genes and in-
hibit gene expression by degrading the target mRNA or
repressing its translation. It is therefore important to identify
novel miR-mediated cancer pathways. In previous studies,
miR-1 has been shown not only to target PIK3CA and inhibit
the tumorigenic properties of lung cancer cells but also to be
useful in predicting lymph node metastasis and postoperative
recurrence in patients with NSCLC [36, 37]. In addition, miR-
1 also targets TAGLN2 in head and neck squamous cell car-
cinoma (HNSCC) [35]. However, to our knowledge, the target
gene of miR-1 in human gastric cancer has not been previous-
ly described. METwas significantly downregulated by ectop-
ic expression of miR-1 in gastric cancer cell lines as shown
above (Fig. 2).
MET, also known as hepatocyte growth factor receptor
(HGFR), is a receptor tyrosine kinase (RTK) that is
overexpressed and/or mutated in a variety of malignancies,
including gastric cancer [38–40]. Expression of MET has
been shown to be correlated with lymph node metastasis, dis-
tant metastasis, and cancer patients’ prognosis [40]. As shown
above, the expression levels of the MET oncogene in gastric
cancer tissues were higher than in matched tissues (Fig. 6h),
indicating that overexpression of MET is related to gastric
tumorigenesis. However, METexpressionwas not significant-
ly different among various pathological grades. This might be
due to the relatively limited samples number.
In conclusion, we showed that restoration of miR-1 expres-
sion in gastric cancer cells results in the inhibition of cell
proliferation and migration. These findings support miR-1 as
a tumor suppressor in gastric cancer. In addition, we demon-
strated that MET may have an oncogenic function, which is
directly regulated by miR-1. The identification of novel miR-
1-regulated MET cancer pathways provides new insights into
potential molecular mechanisms, target therapy, and preven-
tion of gastric cancer.
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